93 results on '"Singer, Jack"'
Search Results
2. Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal gowth factor receptor mutation-positive non-small cell lung Cancer
3. The Cost-effectiveness of Pixantrone for Third/Fourth-line Treatment of Aggressive Non-Hodgkin’s Lymphoma
4. Tolerability and toxicological profile of pixantrone (Pixuvri®) in juvenile mice. Comparative study with doxorubicin
5. The Novel Anthracenedione, Pixantrone, Lacks Redox Activity and Inhibits Doxorubicinol Formation in Human Myocardium: Insight to Explain the Cardiac Safety of Pixantrone in Doxorubicin-Treated Patients
6. Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and Treatment Selection Based on Two Large Randomized Clinical Trials
7. Randomized Phase III Trial Comparing Single-Agent Paclitaxel Poliglumex (CT-2103, PPX) with Single-Agent Gemcitabine or Vinorelbine for the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer
8. Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer
9. Substrate specificity of lysophosphatidic acid acyltransferase β—evidence from membrane and whole cell assays
10. Lisofylline suppresses ex vivo release by murine spleen cells of hematopoietic inhibitors induced by cancer chemotherapeutic agents
11. Corrigendum to “Assessing cardiac safety in oncology drug development” [Am Heart J 214 (2019) 125-133]
12. Results of a Phase 3 Randomised Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Not Eligible for Stem Cell Transplantation
13. Statins Potentiate Aminopeptidase Inhibitor (pro)Drug Activity in Acute Myeloid Leukemia Cells
14. Phase II Clinical Study of the Clinical Efficacy and Safety of Tosedostat in Patients with Myelodysplastic Syndromes (MDS) after Failure of Hypomethylating Agent-Based Therapy
15. Models to Predict Response to JAK-inhibitor Therapy in Patients with Myelofibrosis
16. Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts
17. Pacritinib Targets IRAK1 and Shows Synergy with HDAC and BET Inhibitors in Acute Myeloid Leukemia
18. Relationship of JAK2V617F Allelic Burden (AB) to Demographics, Disease Characteristics, and Response to Therapy in Persist-1, a Randomized Phase III Study of Pacritinib (PAC) Versus Best Available Therapy (BAT) in Patients (pts) with Primary and Secondary Myelofibrosis (MF)
19. Targeting JAK2 By Gene Knockout or Pacritinib Treatment Reduces Gvhd and Xenograft Rejection By Promoting Induced Treg Differentiation
20. Pacritinib, a Dual FLT3/JAK2 Inhibitor, Reduces Irak-1 Signaling in Acute Myeloid Leukemia
21. A Randomized Phase II Study of Tosedostat in Combination with Either Cytarabine or Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
22. Comprehensive Kinase Profile of Pacritinib, a Non-Myelosuppressive JAK2 Kinase Inhibitor in Phase 3 Development in Primary and Post ET/PV Myelofibrosis
23. An Integrated Efficacy and Safety Analysis of Phase 1/2 Studies of Tosedostat, a Novel Aminopeptidase Inhibitor, as Monotherapy for Hematological Malignancies
24. A Phase II Study Of Tosedostat (TST) In Combination With Either Cytarabine Or Decitabine In Newly Diagnosed Older Patients With Acute Myeloid Leukemia (AML) Or High-Risk Myelodysplastic Syndrome (MDS)
25. Targeting Aminopeptidases by Tosedostat (TST) (CHR2797), Alone and with LBH589, Induces Significant Cytotoxicity Against Human Multiple Myeloma (MM) Cells
26. Pixantrone (PIX) Inhibition of Doxorubicinol (DOXOL) Formation in Human Myocardium: Implications for Cardiac Safety in Non-Hodgkin Lymphoma (NHL) Patients with Prior Anthracycline Treatment
27. CPOP-R Versus CHOP-R As First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Phase 2, Randomized, Open-Label, Multicenter Study
28. Pixantrone Dimaleate (PIX) and Comparators In the Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (aNHL): An Analysis of Response and Survival by Gender and Age
29. Phase 3 Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (EXTEND): End of Study Results.
30. LACK of IRON Binding by Pixantrone IS ASSOCIATED with Reduced PRODUCTION of Reactive Oxygen SPECIES and Myoctye Cytotoxicity IN VITRO.
31. Phase III Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin's Lymphoma (EXTEND): Results From the Treatment and Follow-up Periods.
32. P3-019: Serum Cathepsin B (CB) is prognostic and may predict response to therapy in chemotherapy-naive PS2 advanced NSCLC patients treated on two concurrent phase III trials of paclitaxel poliglumex (PPX) vs control treatments (STELLAR 3 and 4)
33. B2-04: Single agent versus combination therapy in advanced NSCLC patients with performance status 2: Results from a regression analysis of STELLAR 3 and 4
34. December Consultation # 9
35. April Consultation # 3
36. Selective Inhibition of Lysophosphatidic Acid Acyltransferase-β by CT32228 Inhibits MAPK and Enhances the Antileukemic Activity of Imatinib in BCR-ABL Expressing Cell Lines Resistant to Imatinib.
37. Molecular Characterization of PS-341 (bortezomib) Resistance: Implications for Overcoming Resistance Using Lysophosphatidic Acid Acyltransferase (LPAAT)-β Inhibitors.
38. Cardiac toxicity of arsenic trioxide
39. Cataract surgical problem
40. Consultation section
41. Direct measurements of lipid peroxidation are present in patients with heart failure: Do they correlate with disease severity?
42. PII: S0886-3350(99)80120-5
43. Frown incision for minimizing induced astigmatism after small incision cataract surgery with rigid optic intraocular lens implantation
44. Replicated evidence on the construct validity of the SCAG (Sandoz Clinical Assessment-Geriatric) scale
45. Correlation between cytogenetic and molecular findings in human chronic myelogenous leukemia lines EM-2 and EM-3
46. Chronic lymphocytosis with neutropenia: Evidence for a novel, abnormal T-cell population associated with antibody-mediated neutrophil destruction
47. Viability of human marrow after long-term cryopreservation
48. Marrow Transplantation for Chronic Myelocytic Leukemia: A Controlled Trial of Cyclosporine Versus Methotrexate for Prophylaxis of Graft-Versus-Host Disease
49. Long-Term Stable Hematopoietic Chimerism Following Marrow Transplantation for Acute Lymphoblastic Leukemia: A Case Report With In Vitro Marrow Culture Studies
50. Human Marrow Stromal Cells: Response to Interleukin-6 (IL-6) and Control of IL-6 Expression
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.